Lung Cancer News

Durvalumab significantly extended PFS compared with placebo among certain patients with locally advanced, unresectable non–small cell lung cancer, according to an interim analysis of a phase 3 trial.

Patients with advanced non–small cell lung cancer more often achieved partial response if pretreated with a PD-1/PD-L1 checkpoint inhibitor prior to salvage chemotherapy, according to retrospective study results presented at the European Lung Cancer Conference.

Levine Cancer Institute at Carolinas HealthCare System launched what institute officials are calling the first-of-its-kind mobile CT unit for lung cancer screening.

The FDA approved pembrolizumab for use in combination with pemetrexed and carboplatin as first-line treatment of metastatic nonsquamous non–small cell lung cancer, according to the drug’s manufacturer.

Women may go longer between lung cancer screenings than men, according to study results presented at the European Lung Cancer Conference.

The addition of selumetinib to docetaxel did not improve PFS among patients with KRAS–mutant non–small cell lung cancer, according to results of the SELECT-1 clinical trial.

SAN DIEGO — Patients with PD-1 positive nonsmall cell lung cancer who were treated with pembrolizumab had improved overall survival and progression-free survival, Brian Lewis, MD, MPH, from Tulane University, told Healio Internal Medicine at the 2017 ACP Internal Medicine annual meeting.

SAN DIEGO — Gregory Kane, MD, chair of the department of medicine at Thomas Jefferson University, discussed the importance of lung cancer screening and how to identify a patient who is eligible for screening at the ACP Internal Medicine Meeting.

The FDA granted breakthrough therapy designation to lorlatinib for the treatment of patients with anaplastic lymphoma kinase–positive metastatic non–small cell lung cancer, according to the drug’s manufacturer.

Intratumor heterogeneity mediated through chromosome instability increased risk for recurrence or death in patients with non–small cell lung cancer, according to results of the TRACERx prospective cohort study published in The New England Journal of Medicine.